CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary Angioedema
Hilary Longhurst, Danny M. Cohn(Amsterdam University Medical Centers), A. Golden(Amsterdam University Medical Centers), Bo Han(Amsterdam University Medical Centers), Mrinal Y. Shah(Amsterdam University Medical Centers), Padmalal Gurugama(Amsterdam University Medical Centers), Michael L. Maitland(Virginia Cancer Institute), John P. Leonard(New York University), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), David Maag(AbbVie (United States)), David Lebwohl(Intellia Therapeutics (United States)), Samantha Soukamneuth(Amsterdam University Medical Centers), Karen Lindsay(Auckland District Health Board), Carri Boiselle(Amsterdam University Medical Centers), Lauré M. Fijen(Amsterdam Neuroscience), Yuanxin Xu(Intellia Therapeutics (United States)), Ahmed M. Abdelhady(Mansoura University), Mark D. McKee(University of Auckland), James S. Butler(Alnylam Pharmaceuticals (United States)), Joseph D Vogel(Amsterdam University Medical Centers), Jessica Seitzer(Intellia Therapeutics (United States)), Eliana D Clark(Amsterdam University Medical Centers), Remy S. Petersen(Amsterdam Neuroscience)
Cited by 177
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k